Filing Flows › Incyte (INCY) › Q3 2026 › vs Q2 2026
Incyte (INCY) Q3 2026 vs Q2 2026 (quarter over quarter)
Incyte's revenue fell $117M (-7%) from $1.7B in Q2 2026 to $1.6B in Q3 2026.
Incyte, Q3 2026: revenue $1.6B (+14% year over year), operating margin -45.5%, net loss $785M, operating cash flow −$675M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $1.6B | $1.7B | −$117M | -7% |
| Other income, net | $19.5M | $53.6M | −$34.1M | -64% |
| Net loss | $785M | −$586M | $1.4B | — |
| Costs & expenses | $2.4B | $1.7B | $634M | +37% |
| Operating costs | $2.3B | $976M | $1.3B | +132% |
| Income tax | $96.0M | $166M | −$70.0M | -42% |
| Cost of revenue | $109M | $105M | $3.8M | +4% |
| Research & development | $1.8B | $517M | $1.3B | +247% |
| SG&A | $364M | $352M | $12.5M | +4% |
| Operating cash sources | $785M | −$586M | $1.4B | — |
| Depreciation & amortization | $24.2M | $26.5M | −$2.3M | -9% |
| Share-based compensation | $69.8M | $67.3M | $2.5M | +4% |
| Working capital & other | $15.5M | −$172M | $187M | — |
| Cash used in operations | $675M | −$508M | $1.2B | — |
| Net loss absorbed | $785M | −$586M | $1.4B | — |
Questions
How much did Incyte's revenue grow quarter over quarter in Q3 2026?
Incyte's revenue fell $117M (-7%) from $1.7B in Q2 2026 to $1.6B in Q3 2026.